Activist investor Starboard Value has ended its fight against Bristol-Myers Squibb's buyout of peer biotechnology company Celgene following recommendations in favor of the deal from Glass Lewis and Institutional Shareholder Services.
This is a developing story. Check back here for more updates.
from Top News & Analysis https://ift.tt/2TI6JhN
No comments:
Post a Comment